SUBVERIX™ / SCIENCE UPDATE

Science
news.

Selected research, technologies and development signals that may shape the future of peptide science.

SELECTED PUBLICATIONS

Evidence before
promises.

STABILITY AND STORAGE

A peptide does not begin at the moment of use

Why lyophilisation, moisture, oxygen, transport and the moment of reconstitution matter as much as declared material purity.

An original SUBVERIX™ analysis connecting technical reference material into one practical assessment standard.

five technical references combined into a practical evaluation framework
READ THE SUBVERIX™ ANALYSIS

ANALYTICS AND SEQUENCING

A nanopore reads a peptide residue by residue

EANPSeq combines controlled peptide shortening, nanopore measurement and machine learning for single-molecule sequence identification.

The method reads successive fragments generated by exopeptidase digestion and can localise post-translational modifications. It is an analytical-technology study, not a finished quality test for SUBVERIX™ products.

1 AAsequence readout at single-amino-acid resolution
READ THE SOURCE PUBLICATION

PEPTIDE DESIGN

Computationally designed peptide nanopores

A new framework designs short peptides that self-assemble into stable membrane channels and can be tuned at sequence level.

The authors combined molecular-dynamics simulations with experimental validation. Lead designs showed antimicrobial activity in preclinical models. These findings apply to the studied candidates and cannot be transferred to unrelated peptides or commercial products.

52×modular sequence templates described by the design platform
READ THE SOURCE PUBLICATION

THERMAL STABILITY

Degradation is not the only route to activity loss

An analysis of balixafortide links microheterogeneity, structural rearrangement and degradation to bioactivity loss under thermal stress.

The study illustrates why one purity value cannot describe the full stability of a peptide. Topological change and microheterogeneity may become biologically meaningful when assessment is limited to a simple chromatographic headline.

two observed inactivation routes: degradation and conformational reorganisation
READ THE SOURCE PUBLICATION

MULTI-RECEPTOR PEPTIDES

Retatrutide in a randomised phase 2 trial

A clinical study of a GIP–GLP-1–glucagon receptor agonist illustrates the development of peptides acting on multiple metabolic pathways.

The phase 2 results require confirmation in further clinical research and should not be treated as evidence for unrelated products.

PHASE 2a clinical-development stage, not a market authorisation
READ THE SOURCE PUBLICATION